Apimeds Pharmaceuticals US (APUS) Notes Payables (2023 - 2025)

Apimeds Pharmaceuticals US's Notes Payables history runs 3 years deep, the most recent figure standing at $7.1 million for Q4 2025.

• Quarterly Notes Payables rose 2736.51% year-over-year to $7.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.1 million (up 2736.51% YoY) and the FY2025 annual result came in at $7.1 million, up 2736.51% from the prior year.
• Notes Payables was $7.1 million for Q4 2025 at Apimeds Pharmaceuticals US, up from $250000.0 in the prior quarter.
• Across five years, Notes Payables topped out at $7.1 million in Q4 2025 and bottomed at $250000.0 in Q4 2024.
• A 3-year average of $2.0 million and a median of $258445.5 in 2023 frame the typical range for Notes Payables.
• Annual changes were most pronounced in 2024 — Notes Payables declined 6.33% — and 2025, when it soared 2736.51%.
• Apimeds Pharmaceuticals US's Notes Payables stood at $266891.0 in 2023, then decreased by 6.33% to $250000.0 in 2024, then surged by 2736.51% to $7.1 million in 2025.
• Business Quant data shows APUS's Notes Payables at $7.1 million in Q4 2025, $250000.0 in Q1 2025, and $250000.0 in Q4 2024.